Neurophet, Inc.
KKRX:3805505,640.00
KRW
-220.00
(-3.75%)
ISIN
KR7380550004
Return %
Stock
S&P 500
1Y
-73.08
13.14
3Y
- -
80.78
5Y
- -
67.74
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Junkil Been
- Full Time Employees
- 35
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Samwon Tower Seoul SL South Korea
- IPO Date
- Jul 25, 2025
- Website
- neurophet.com
- Similar Companies
- Business
- Neurophet Inc. operates as a pioneering neuroscience company, dedicated to developing advanced medical artificial intelligence solutions for brain science and neurological conditions. The company offers a suite of AI-driven products, including Neurophet AQUA, software designed to assist in diagnosing degenerative brain disorders like Alzheimer's disease and multiple sclerosis by quantitatively analyzing brain MRI data for atrophy, white matter hyperintensities, and lesions. Its specialized variant, Neurophet AQUA AD, aids in the prescription and monitoring of Alzheimer's treatments, encompassing the assessment of drug efficacy and potential side effects. Further extending its diagnostic capabilities, Neurophet SCALE PET provides quantitative analysis of PET images to evaluate various biomarkers, such as amyloid and tau protein deposits, playing a crucial role in managing anti-amyloid therapies and monitoring related imaging abnormalities. For therapeutic applications, Neurophet tES LAB offers AI-powered software that generates personalized 3D brain models from MRI scans to simulate and plan transcranial electrical stimulation for conditions like stroke rehabilitation and depression. This is complemented by Neurophet innk, a non-invasive electrical stimulation device aimed at functional recovery and rehabilitation in patients with brain disorders. Beyond its product portfolio, the company provides expert consulting for design and quality management systems and has expanded into imaging contract research organization (CRO) services, supporting pharmaceutical companies in clinical trials for new brain disease treatments. Neurophet has achieved significant milestones, including expanded U.S. FDA 510(k) clearance for Neurophet AQUA's multiple sclerosis assessment in November 2024, and is actively pursuing an initial public offering on the Kosdaq market in 2025, having passed preliminary review in August 2024. The company, established in 2016, is headquartered in Seoul, South Korea.